Bibliography
- SCHWEBKE JR: Gynecologic consequences of bacterial vaginosis. Obstet. Gynecol. Clin. N. Am. (2003) 30(4):685–694.
- ••Excellent review underscoring theimportance of proper diagnosis and treatment of BY.
- SOBEL JD: Vaginitis. N Engl. J. Med. (1997) 337(26):1896–1902.
- MIKAMO H, KAWAOE K, IZUMI K, WATANABE K, UENO K, TAMAYA T: Comparative study on vaginal or oral treatment of bacterial vaginosis. Chemotherapy (1997) 43(1):60–68.
- •Provides an understanding to support rationale for local treatment of vaginal infections.
- WEINSTEIN L, HENZEL MR, TSINA IW: Vaginal retention of 2% butoconazole nitrate cream: comparison of a standard and a sustained-release preparation. Clin. Ther. (1994) 16(6):930–934.
- •The first clinical study to demonstrate increased vaginal retention of medication with proprietary drug delivery system.
- THOMPSON DJ, LEVINSON RS: A bioadhesive topical drug delivery system. Drug Delivery Systems & Sciences (2002) 2(1):17–19.
- ••An excellent review highlighting clinical advantages with a unique bioadhesive delivery system for the treatment of VVC.
- KV Pharmaceutical.
- BROWN D, HENZL MR, KAUFMAN RH: Butoconazole nitrate 2% for vulvovaginal candidiasis. New, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. Gynazole 1 Study Group. J. Repr. Med. (1999) 44(11):933–938.
- •Pivotal clinical trial demonstrating equivalent efficacy with a low, single-dose of butoconazole nitrate compared with traditional 7-day treatment for VVC.
- KV Pharmaceutical.
- Gynazole-1® Package Insert. Ther-Rx Corporation.
- Diflucan® Package Insert. Pfizer Pharmaceuticals.
- KV Pharmaceutical.
- SCHLICHT JR: Treatment of bacterial vaginosis. Ann. Pharmacother. (1994) 28(4):483–487.
- AMSEL R, TOTTEN PA, SPIEGEL CA, CHEN KC, ESCHENBACH D, HOLMES KK: Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am. J. Med. (1983) 74(1):14–22.
- CAREY JC, KLEBANOFF MA: Bacterial vaginosis and other asymptomatic vaginal infections in pregnancy. Curr. Womens Health Rep. (2001) 1(1):14–19.
- PAAVONEN J, MANGIONI C, MARTIN MA, WAJSZCZUK GP: Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet. Gynecol. (2000) 96(2):256–260.
- FERRIS DG, LITAKER MS, WOODWARD L, MATHIS D, HENDRICH J: Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J. Fam. Pract. (1995) 41(5):443–449.
- ANDRES FJ, PARKER R, HOSEIN I, BENRUBI GI: Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial. South. Med. J. (1992) 85(1 0:1077–1080.
- Metro-Gel® Package Insert. M Pharmaceuticals.
- Cleocin® Vaginal Cream. Pfizer Pharmaceuticals.
- CUNNINGHAM FE, KRAUS DM, BRUBAKER L, FISCHER JH: Pharmacokinetics of intravaginal metronidazole gel. J. Clin. Pharmacol. (1994) 34(10:1060–1065.
- KV Pharmaceutical
- Cleocin Vaginal Ovules. Pfizer Pharmaceuticals.
- KV Pharmaceuticals.
- RICHTER A, ANTON SE, KOCH P, DENNETT SL: The impact of reducing dose frequency on health outcomes. Clin. Ther. (2003) 25(8):2307–2335.
- ••An excellent and comprehensive discussion on the importance of a reducing dose frequency can positively have on compliance and ultimately, overall health objectives.
Website
- http://www.fda.gov/cder/drug/infopage/ miconazole/default.htm Science background: safety of miconazole vaginal cream and suppositories (2001). FDA talk paper.